[Recommendations for the management of pancreatic cancer type adenocarcinoma: A consensus statement reached during the 2015 Latin American Symposium on Gastroenterological Oncology]

Rev Med Chil. 2016 Oct;144(10):1305-1318. doi: 10.4067/S0034-98872016001000010.
[Article in Spanish]

Abstract

Pancreatic cancer is a malignancy of great impact in developed countries and is having an increasing impact in Latin America. Incidence and mortality rates are similar for this cancer. This is an important reason to offer to the patients the best treatments available. During the Latin American Symposium of Gastroenterology Oncology (SLAGO) held in Viña del Mar, Chile, in April 2015, a multidisciplinary group of specialists in the field met to discuss about this disease. The main conclusions of this meeting, where practitioners from most of Latin American countries participated, are listed in this consensus that seek to serve as a guide for better decision making for patients with pancreatic cancer in Latin America.

MeSH terms

  • Adenocarcinoma / therapy*
  • Antimetabolites, Antineoplastic / therapeutic use
  • Chemoradiotherapy
  • Consensus Development Conferences as Topic
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Disease Management*
  • Gemcitabine
  • Humans
  • Latin America
  • Pancreatic Neoplasms / therapy*
  • Practice Guidelines as Topic*

Substances

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Gemcitabine